Monte, Andrew A.
,
Calello, Diane P.
Gerona, Roy R.
Hamad, Eike
Campleman, Sharan L.
Brent, Jeffery
Wax, Paul
Carlson, Robert G.
Funding for this research was provided by:
National Institute of General Medical Sciences (K23 GM110516)
National Institutes of Health (UL1 TR001082)
NIH (NIH R56 DA038366)
Article History
Received: 19 October 2016
Revised: 27 January 2017
Accepted: 2 February 2017
First Online: 10 April 2017
Compliance with Ethical Standards
:
: The contents of this work are the sole responsibility of the authors and do not necessarily represents the views of the National Institutes of Health (NIH). The authors declare that they have no conflict of interest.
: Dr. Monte receives support from NIH 1 K23 GM110516 and NIH CTSI UL1 TR001082. Dr. Monte has a patent pending for a synthetic cannabinoid clinical assay and has been awarded funding through the Department of Defense for examination of patterns of use of synthetic cannabinoids and assay development. A subset of the data collected was funded by the grant NIH R56 DA038366 (Carlson, Sheth, Boyer, PIs).